Catalase deficiency may complicate urate oxidase (rasburicase) therapy
László Góth1, N William Bigler
1Department of Clinical Biochemistry, Molecular Pathology and Clinical Analytical Chemistry, Medical College, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. goth@dote.hu
Abstract:
Patients with low (inherited and acquired) catalase activities who are treated with infusion of uric acid oxidase because they are at risk of tumour lysis syndrome may experience very high concentrations of hydrogen peroxide. They may suffer from methemoglobinaemia and haemolytic anaemia which may be attributed either to deficiency of glucose-6-phosphate dehydrogenase or to other unknown circumstances. Data have not been reported from catalase deficient patients who were treated with uric acid oxidase. It may be hypothesized that their decreased blood catalase could lead to the increased concentration of hydrogen peroxide which may cause haemolysis and formation of methemoglobin. Blood catalase activity should be measured for patients at risk of tumour lysis syndrome prior to uric acid oxidase treatment.
Related Concept Videos
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Inborn Errors of Metabolism
Urea Cycle
Jaundice


